[The change of thioredoxin system in myocardial tissue of type 2 diabetic rats undergoing myocardial injury].
The aim of the present study is to investigate the change of thioredoxin (Trx) system in myocardial tissue of type 2 diabetic rats after myocardial injury and the underlying mechanism. Adult Sprague Dawley rats were randomly divided into two groups: normal control (NC) group and diabetes (DM) group. Rats in DM group were subjected to high-sugar, high-fat diet and streptozotocin (STZ) injection. Rats in NC group were only given normal diet and equal amount of citric acid buffer injection. At week 1, 2, 4, 12, 21 after STZ injection, plasma glucose concentration and the concentrations of insulin, creatine kinase MB (CK-MB), cardiac troponin I (cTnI) in serum were measured. Myocardial Trx and thioredoxin reductase (TR) activities, as well as caspase-3 activity, were determined by respective assay methods. Protein and mRNA levels of Trx, TR, Trx interacting protein (TXNIP) were determined by Western blot and real time PCR, respectively. The results showed that type 2 diabetic rat model was successfully established at week 1 after STZ injection, and myocardial injury was induced from week 2. Moreover, caspase-3 activity was significantly increased at week 4, 12 in diabetic rats. The activities of myocardial Trx and TR in diabetic rats was decreased from week 2, and continually aggravated as the disease developed. Compared with those in NC group, the mRNA levels of Trx1, Trx2, TR1, TR2 in DM group decreased at week 4, and then increased in week 12. In DM group, the protein levels of Trx1, Trx2, TR1 and TR2 increased significantly at week 12. The mRNA expressions of myocardial TXNIP in diabetic rats were significantly increased at week 4, 12, 24 and protein expression was increased at week 12. These results suggest diabetes can decrease myocardial Trx, TR activity, inducing myocardial cell apoptosis and heart injury. The inhibitory effect of diabetes is mainly associated with TXNIP up-regulation and Trx nitration.
Zhao
Xiao-Qin
XQ
Department of Physiology, Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, China.
Zhao
Jun-Jie
JJ
Li
Xiao-Yu
XY
Zhang
Yan
Y
Jiao
Xiang-Ying
XY
D000818:Animals; D017209:Apoptosis; D002352:Carrier Proteins / Q000378:metabolism; D053148:Caspase 3 / Q000378:metabolism; D018797:Cell Cycle Proteins; D052279:Creatine Kinase, MB Form / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D059305:Diet, High-Fat; D007328:Insulin / Q000097:blood; D009206:Myocardium / Q000473:pathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin; D013880:Thioredoxin-Disulfide Reductase / Q000378:metabolism*; D013879:Thioredoxins / Q000378:metabolism*; D019210:Troponin I / Q000097:blood; D015854:Up-Regulation
D002352:Carrier Proteins; D018797:Cell Cycle Proteins; D007328:Insulin; C493796:TXNIP protein, rat; D019210:Troponin I; D013879:Thioredoxins; D013311:Streptozocin; D013880:Thioredoxin-Disulfide Reductase; D052279:Creatine Kinase, MB Form; C505410:Casp3 protein, rat; D053148:Caspase 3